

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 053466/0201

Paper # 10412  
12/21/98

In re patent application of  
Tadamitsu KISHIMOTO  
Serial No. 08/817,507

Group Art Unit: 1642

Examiner: J. Reeves

Filed: April 1, 1997

For: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF  
DISEASES CAUSED IL-6 PRODUCTION

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This amendment is supplemental to the Amendment under 37 CFR §1.111 filed on October 13, 1998 in response to the Office Action mailed on May 13, 1998. We believe that no fee is required. However, in the event that a fee is required, please consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.18 from Account No. 19-0741.

RECEIVED  
TECH CENTER 1600/2900  
98 DEC - 2 AMTD: 5

REMARKS

In further response to rejections under 35 U. S. C. § 112, first paragraph and second paragraph, we now provide a copy of the deposit receipt from the National Institute of Bioscience and Human-Technology, a Budapest Treaty recognized depository, showing that the hybridoma PM-1 was deposited as FERM BP-2998 on July 10, 1990. The deposit was made by one of the present inventors, Dr. Tadamitsu Kishimoto.

CONCLUSION

In light of the previous response and the enclosed evidence of deposit that hybridoma PM-1 is deposited as accession number FERM BP-2998, applicants submit that all claims are in condition for allowance, and they solicit an early indication to that effect. Should the examiner believe that further discussion of any remaining issues would advance

the prosecution, he is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

December 2, 1998  
Date

  
Stephen B. Maebius  
Reg. No. 35,264

FOLEY & LARDNER  
3000 K Street, N.W., Suite 500  
Washington, DC 20007-5109  
(202) 672-5300